December 4, 2024

Pulse Bliss

most important health challenges

MGA MedTech, France’s First 4.0 Sustainable MedTech Facility

MGA MedTech, France’s First 4.0 Sustainable MedTech Facility

In its new 4.0 facility, MGA MedTech designs and manufactures advanced medical devices and diagnostics equipment for its clients. During the inauguration of the facility, we heard from key players who brought the project to life.

On September 11, 2024, MGA MedTech marked a significant milestone in the medtech industry with the inauguration of its new state-of-the-art facility in Mably, France. Attended by high-profile figures, including Nicolas Dufourcq, CEO of Bpifrance, and Patrick Martin, President of MEDEF, the event showcased France’s first fully digitalized, robotized, and sustainable 4.0 factory, dedicated to accelerating innovation in in vitro diagnostics and cellular and gene therapies.

This new facility highlights MGA MedTech’s commitment to reshaping the future of healthcare by integrating cutting-edge technology with eco-friendly industrial practices. Serving a rapidly growing market for diagnostics and personalized medicine, MGA MedTech is positioned as a key player in both advancing medical technologies and setting a new standard for sustainable industrial development.

Innovation at the Heart of MGA MedTech’s Mission

MGA MedTech, a dynamic startup initiated by MGA Technologies, has developed this facility to support the production of high-tech instruments for diagnostics and the processing of biotherapeutic products. The factory’s focus on medical devices, in vitro diagnostic (IVD) equipment, and innovative medical therapies positions the company at the forefront of the industry.

Hervé de Malliard, President of MGA MedTech, emphasized the company’s mission during his inaugural speech:

“This 4.0 facility, designed to be a model of sustainability and innovation, is the fruit of a collective vision for the future. At MGA MedTech, we firmly believe that technology and ecology can come together to improve health outcomes for all. This site embodies our ambition to accelerate the use of advanced technologies in healthcare.”

Architectural Innovation and Sustainability

The architectural design of the facility is as innovative as the technology it produces. A key feature of the building is its sawtooth roof, a modern adaptation of traditional industrial architecture. These roofs will optimize the performance of the building’s photovoltaic panels, once installed on the south-facing slopes to maximize energy generation, while the north-facing glass panels provide ample natural light to the production workshops.

Built with a wooden frame and concrete structural elements for enhanced thermal inertia, the facility’s green façades contribute to a design that exceeds RE-2020 energy standards by 25%. These eco-friendly design elements ensure the building not only meets but surpasses the highest energy efficiency requirements.

The site also features a geothermal heating system, utilizing 11 wells drilled to a depth of 140 meters, ensuring that the facility is largely energy self-sufficient. MGA MedTech aims to offset the carbon footprint of the building’s construction by the early 2030s, making it a true benchmark for sustainable industrial development.

Leading the Industry 4.0 Revolution

This facility is more than just a factory; it’s a modular, full-digital production site designed to adapt to changing needs in the medical device sector. With a strong emphasis on automation and digitalization, the factory operates with minimal paper waste, relying on a fully digital system to streamline workflows, manage data, and track production in real-time.

MGA MedTech’s R&D team, based in Mably, specializes in microfluidics, cell biology, mecatronics, and embedded electronics, all of which are critical technologies for the future of personalized medicine. With a projected annual growth rate of 6% for in vitro diagnostics instruments, 9.4% for bioproduction, and over 35% for organ-on-chip technologies, MGA MedTech is well-positioned to meet the evolving demands of the medtech sector well into the 2030s.

As noted by Yves Nicolin, Mayor of Roanne and President of Roannais Agglomération, during the inauguration:

“This facility represents more than just job creation. It signals the return of high-tech industrialization to our region, supporting medical innovation while upholding our commitment to sustainable development. This is a proud moment for the Roannais, as we position ourselves as a center of excellence in medical technology.”

Partnering for the Future of Health Innovation

MGA MedTech’s success is deeply rooted in strategic partnerships. The company collaborates with major industrial players, such as Sanofi, which is set to open its EVF (Evolutive Facility) in 2025, a bioproduction plant that MGA MedTech helped design. In addition, STILLA Technologies partnered with MGA to develop R&D projects centered on precision genetic analysis, with MGA MedTech providing the technical expertise for the development and industrialization of cutting-edge devices.

This spirit of collaboration extends to MGA’s role as a Contract Development and Manufacturing Organization (CDMO). By providing manufacturing and technical expertise, MGA MedTech helps startups and major industry players alike de-risk their production processes. This allows clients to focus on open innovation while leveraging MGA MedTech’s advanced infrastructure and collaborative teams to bring their devices to market more efficiently.

A Vision for the Future of Medicine

The opening of MGA MedTech’s 4.0 factory represents a major leap forward for the company and the industry at large. With its advanced capabilities in robotics, automation, and biotechnologies, MGA MedTech is poised to support the development of the next generation of medical devices and biotherapeutic products. The company’s focus on flexibility, scalability, and sustainability ensures that it can meet the rapidly growing demand for advanced diagnostics and treatments, particularly in personalized medicine.

As Patrick Martin, President of MEDEF, noted,

“This facility is a beacon of industrial renewal for France, proving that we can successfully combine technological excellence with environmental responsibility. MGA MedTech is setting a new standard for the medtech industry, and its impact will be felt for years to come.”

With a clear commitment to both innovation and sustainability, MGA MedTech is shaping the future of medical technology. By harnessing the power of Industry 4.0, the company is not only revolutionizing the medtech sector but also ensuring that the innovations of today will lead to a healthier, more sustainable tomorrow.

This comprehensive and forward-thinking approach demonstrates MGA MedTech’s ability to align technological advancements with the highest environmental standards, securing its position as a leader in the medical and biotech industries. With a strong foundation in innovation, collaboration, and sustainability, MGA MedTech is well on its way to becoming a global benchmark in medtech manufacturing.

link